PROTEINURIA TESTING:

Dipstick, ACR, PCR, and 24-Hour Collections — Clearing the Confusion Once and for All

Dr Neeraj Manikath , claude.ai

1. Clinical Introduction: A Case That Should Have Been Simple

A 52-year-old woman with type 2 diabetes of eight years' duration presents to the nephrology outpatient clinic. Her family physician has referred her for "worsening proteinuria". On review, there are three separate urine results in the past six months: a dipstick showing 2+ protein, an albumin-to-creatinine ratio (ACR) of 38 mg/mmol, and a 24-hour urine collection reporting total protein of 520 mg/day. The referral letter concludes: "Proteinuria escalating — possible nephrotic range."

At clinic, a repeat first-morning ACR is 31 mg/mmol. The patient has no oedema, no haematuria, and her eGFR is 71 mL/min. Her referral triggered specialist review, patient anxiety, additional investigations, and a three-month wait. The proteinuria was never escalating. The clinician was simply not comparing like with like.

This scenario plays out in clinics worldwide every day. Proteinuria measurement is among the most requested investigations in internal medicine — yet it remains among the most misinterpreted. The confusion stems from a genuine proliferation of testing modalities, each measuring subtly different things, each with its own clinical niche, reference range, and threshold for action.

Globally, chronic kidney disease (CKD) affects approximately 850 million people, and proteinuria is both its cardinal biomarker and an independent cardiovascular risk factor [1]. Getting proteinuria measurement right is not a laboratory technicality — it is a clinical imperative that directly shapes diagnosis, prognosis, cardiovascular risk stratification, and drug selection.

This article will cut through the confusion. By the end, you will know exactly which test to order, when, and how to interpret the result.

2. Pathophysiology — Only What You Need to Understand the Tests

The Normal Glomerular Filtration Barrier

Under normal conditions, the glomerular filtration barrier — comprising the fenestrated endothelium, glomerular basement membrane (GBM), and podocyte foot processes — restricts protein passage by size and charge. The GBM carries a net negative charge, repelling albumin (which is also negatively charged). A small quantity of protein is filtered but the vast majority is reabsorbed by proximal tubular cells via megalin-cubilin receptor-mediated endocytosis.

In health, urine protein excretion is typically less than 150 mg per day, of which albumin constitutes only 10–30 mg/day. The remainder is Tamm-Horsfall protein (uromodulin), tubular secretory proteins, and small amounts of immunoglobulin light chains.

Why Proteinuria Occurs

Proteinuria arises through three distinct mechanisms — and recognising which is operative changes clinical management fundamentally:

• Glomerular proteinuria: Disruption of the filtration barrier (podocyte injury, immune complex deposition, haemodynamic stress) allows excessive albumin leak. This is the dominant pattern in diabetic nephropathy, glomerulonephritis, and focal segmental glomerulosclerosis (FSGS). It is predominantly albuminuric.

• Tubular proteinuria: Proximal tubular damage impairs reabsorption of small molecular weight proteins (beta-2-microglobulin, retinol-binding protein, alpha-1-microglobulin). The filtrate is relatively protein-rich but albumin-poor. Causes include Fanconi syndrome, heavy metal toxicity, and some drugs (e.g., tenofovir). The ACR may be modestly elevated but PCR is disproportionately higher.

• Overflow proteinuria: Overproduction of a freely-filtered protein overwhelms tubular reabsorptive capacity. The classic example is Bence-Jones proteinuria in myeloma — immunoglobulin light chains are not detected by standard albumin dipsticks. A negative dipstick in a suspected myeloma patient does NOT exclude significant proteinuria.

PATHOPHYSIOLOGY PEARL

The ACR specifically measures albumin — it is blind to Bence-Jones protein, retinol-binding protein, and other low-molecular-weight proteins. A normal ACR does not equal absent proteinuria. Use PCR (or spot urine protein, or 24-hour total protein) when overflow or tubular proteinuria is suspected.

Understanding this tripartite mechanism is the clinical foundation for choosing the right test. Now let us examine each modality in detail.

3. The Tests Explained: What Each One Actually Measures

3.1 Urine Dipstick — The Screening Tool

The urinary dipstick detects protein (predominantly albumin) through the "protein error of pH indicators" — typically tetrabromophenol blue, which changes colour from yellow through green to blue with increasing protein concentrations. Results are reported as negative, trace, 1+, 2+, 3+, and 4+, corresponding approximately to the following albumin concentrations:

Dipstick Result	Approx. Protein (mg/dL)	Comment
Negative	< 10	Normal
Trace	10–20	May be physiological; repeat on first-morning sample
1+	30	Clinically significant; confirm with ACR/PCR
2+	100	Significant; warrants quantification
3+	300	Significant; priority quantification + nephrology review
4+	> 2000	Potentially nephrotic-range; urgent quantification

CRITICAL DIPSTICK LIMITATIONS

1. Concentration-dependent: a dilute urine (SG < 1.010) will underread; a concentrated urine (SG > 1.030) will overread.

2. Detects albumin only — misses Bence-Jones protein, tubular proteins, and myoglobin.

3. False positives: alkaline urine (pH > 8), prolonged immersion, contamination with antiseptics (chlorhexidine), blood, semen, mucus.

4. False negatives: dilute urine, non-albumin proteinuria, acidic urine.

5. NOT suitable for quantification — use ACR, PCR, or 24-hour collection.

The dipstick's role is screening, not quantification. A positive dipstick opens the diagnostic conversation; it does not close it. Every clinically significant dipstick positive requires quantitative follow-up.

3.2 Albumin-to-Creatinine Ratio (ACR) — The Workhorse of CKD Monitoring

The ACR is performed on a spot (random) urine sample, most reliably the first-morning void (FMV), and corrects albumin concentration for urine dilution by expressing it as a ratio to creatinine concentration. This elegantly sidesteps the need for timed collections, assuming creatinine excretion is relatively constant.

Category	ACR (mg/mmol)	ACR (mg/g)	Historical Term	Clinical Significance
A1 — Normal to mildly increased	< 3	< 30	Normoalbuminuria	Normal; annual monitoring if CKD risk factors
A1 — High normal	3–30	30–300	Microalbuminuria	Early diabetic nephropathy / CKD marker; RAAS initiation
A2 — Moderately increased	3–30	30–300	Microalbuminuria	As above (KDIGO 2024 reclassification — see Section 6)
A3 — Severely increased	> 30	> 300	Macroalbuminuria / Clinical proteinuria	High CKD progression risk; specialist referral threshold
Nephrotic range	> 220	> 2200	Nephrotic-range proteinuria	Urgent nephrology; likely glomerular disease

Units trap: Many laboratories report ACR in mg/mmol (SI units); US and some other labs use mg/g. The conversion factor is 1 mg/mmol = approximately 8.84 mg/g. The KDIGO threshold of 3 mg/mmol corresponds to 30 mg/g. Confusing these units is a common and consequential error.

ACR TIMING MATTERS

Preferred: First-morning void (FMV) — correlates best with 24-hour excretion, avoids orthostatic (postural) albuminuria, and is least subject to physiological fluctuation.

Random spot: Acceptable if FMV not available; specify collection time on request form.

Post-exercise, febrile, or post-intercourse specimens will be falsely elevated — always note clinical context.

KDIGO recommends TWO of THREE elevated ACR samples (over 3 months) to confirm persistent proteinuria before making a CKD diagnosis.

3.3 Protein-to-Creatinine Ratio (PCR) — The Broader Net

The PCR measures total urinary protein (not just albumin) as a ratio to creatinine. It detects the full spectrum of proteinuria — glomerular, tubular, and overflow — and is the preferred test when non-albumin proteinuria is suspected.

PCR (mg/mmol)	PCR (mg/g)	Approximate 24-hr Equivalent	Clinical Category
< 15	< 150	< 150 mg/day	Normal
15–50	150–500	150–500 mg/day	Mild proteinuria — confirm, monitor
50–100	500–1000	500–1000 mg/day	Moderate — investigate underlying cause
> 100	> 1000	> 1 g/day	Heavy proteinuria — specialist review
> 350	> 3500	> 3.5 g/day	Nephrotic-range

ACR vs PCR — the key clinical distinction: In glomerular disease (e.g., diabetic nephropathy, IgA nephropathy), proteinuria is predominantly albuminuric, and ACR closely tracks PCR. However, in myeloma, tubular disorders, and Fanconi syndrome, the PCR will be disproportionately elevated relative to the ACR. A high PCR with a disproportionately lower ACR should trigger an urgent protein electrophoresis (UPEP) and Bence-Jones protein assay.

3.4 The 24-Hour Urine Collection — Still the Gold Standard (for Now)

The 24-hour urine protein excretion remains the reference standard for proteinuria quantification. It captures the full diurnal variation in protein excretion and is unaffected by changes in muscle mass (which influence creatinine-based ratios). However, its utility is constrained by a fundamental practical problem: patient compliance.

Studies consistently show that 30–50% of 24-hour collections are incomplete [2], leading to systematic underestimation of protein excretion. The adequacy of a collection is assessed by checking the creatinine content:

VALIDATING A 24-HOUR COLLECTION — CREATININE ADEQUACY CHECK

Expected 24-hr creatinine excretion (roughly):

Men: 15–20 mmol/day (150–200 mg/kg/day in older literature; ~1500–2000 mg/day)

Women: 10–15 mmol/day (~1000–1500 mg/day)

Elderly and sarcopenic patients: Expect LOWER creatinine excretion — do not flag as inadequate.

Tip: A total creatinine of < 8 mmol/day in a man or < 6 mmol/day in a woman strongly suggests an incomplete collection — discard and repeat.

The 24-hour collection is most valuable in: clinical trial settings requiring precise quantification; preoperative assessment of renal protein excretion before donor nephrectomy; monitoring nephrotic syndrome responses to treatment; and when creatinine-based ratios are unreliable (extreme muscle mass, amputees, body builders, severe sarcopenia).

3.5 Other Tests You Need to Know

Urine Protein Electrophoresis (UPEP) and Immunofixation

UPEP separates urinary proteins by charge and molecular weight, identifying the predominant protein type. Immunofixation characterises monoclonal bands. Essential in any patient with unexplained proteinuria over 1 g/day, particularly if the ACR-to-PCR discordance is high, if there is unexplained renal failure, anaemia, or bone pain — the CRAB criteria (Calcium, Renal, Anaemia, Bone) of myeloma.

Bence-Jones Protein (Free Light Chain Assay)

Serum free light chain (FLC) ratio is now preferred over urine Bence-Jones protein testing for myeloma screening. However, urine immunofixation remains indispensable for monitoring light chain disease.

Selective Protein Indices (Selectivity Index)

In nephrotic syndrome, the protein selectivity index (ratio of IgG to transferrin clearance) was historically used to differentiate minimal change disease (high selectivity — mainly albumin leaks) from FSGS (low selectivity — larger proteins leak too). It has largely been superseded by renal biopsy in practice, but the concept remains useful at the bedside.

Beta-2-Microglobulin and Alpha-1-Microglobulin

These are low-molecular-weight proteins filtered freely at the glomerulus and almost entirely reabsorbed by the proximal tubule. Elevated urinary levels indicate tubular dysfunction. Alpha-1-microglobulin is preferred to beta-2-microglobulin because it is stable across a wide urine pH range (beta-2-microglobulin degrades at pH < 5.5).

4. Clinical Pearls 🪙 — Counterintuitive, High-Yield Observations

🪙 Pearl 1: A Negative Dipstick Does NOT Rule Out Clinically Significant Proteinuria

If you order a dipstick in a patient with suspected myeloma, significant tubular disease, or light chain cast nephropathy, you will miss the diagnosis. Bence-Jones protein is not detected by dipstick. Always order a PCR and UPEP in this clinical context — never just a dipstick.

🪙 Pearl 2: Orthostatic (Postural) Proteinuria — A Benign Mimic

Young, thin individuals (particularly adolescents and young adults) can excrete significant protein only in the upright position. This orthostatic proteinuria is benign, with no long-term renal sequelae. Diagnosing it correctly avoids unnecessary nephrology referrals and patient anxiety.

How to identify it: Split urine collection — recumbent overnight collection negative, ambulatory daytime collection elevated. Alternatively, a consistently normal FIRST-MORNING VOID ACR/PCR in a patient with elevated random specimens points strongly to orthostatic proteinuria.

🪙 Pearl 3: Fever, Exercise, and Heart Failure Transiently Elevate Proteinuria

Acute illness, fever, vigorous exercise (including a 5K run the morning before clinic), and acute decompensated heart failure all cause transient glomerular haemodynamic changes resulting in functional proteinuria. Repeating the ACR four to six weeks after resolution of the acute trigger avoids misclassifying these patients with CKD A2.

🪙 Pearl 4: Haematuria Elevates Both Dipstick and ACR

Significant microscopic or macroscopic haematuria will falsely elevate dipstick protein readings. Blood contains plasma proteins (predominantly albumin) that contribute to both the dipstick colour reaction and to the ACR. If dipstick is simultaneously positive for blood and protein, interpret the protein result with caution and repeat after haematuria resolves.

🪙 Pearl 5: The ACR Can Fluctuate up to 40% Within an Individual Day-to-Day

Biological variability means that a single ACR result has wide confidence intervals. This is why KDIGO mandates confirmation with two of three samples over three months. Do not escalate management or make major diagnostic decisions based on a single elevated ACR — particularly if borderline.

5. Oysters 🦪 — Hidden Gems Most Clinicians Miss

🦪 Oyster 1: ACR and PCR Are NOT Interchangeable — Even in Glomerular Disease

It is tempting to think that because diabetic nephropathy is albuminuric, ACR and PCR tell the same story. They do not — completely. PCR typically runs higher than ACR (numerically) because it captures all protein, not just albumin. Comparing an ACR from six months ago with a PCR today and concluding that proteinuria has worsened is a common, consequential error. Always compare like with like.

🦪 Oyster 2: The KDIGO 2024 Update Has Retired the Term 'Microalbuminuria'

The KDIGO 2024 CKD guidelines have formally retired the term 'microalbuminuria', which caused significant confusion (it does not refer to small amounts of a special type of albumin — it referred to amounts detectable only by sensitive assays, below the threshold of standard dipstick). The updated classification uses A1, A2, and A3 categories based on ACR thresholds. Clinicians still using the old terminology risk miscommunication with colleagues and patients.

🦪 Oyster 3: Muscle Mass Profoundly Affects Creatinine-Based Ratios

The ACR and PCR assume relatively stable daily creatinine excretion. In patients with severe muscle wasting (cancer cachexia, end-stage liver disease, amputees, spinal cord injury, very elderly frail patients), creatinine excretion is dramatically reduced. The ACR and PCR will therefore OVERESTIMATE proteinuria relative to a true 24-hour collection. In such patients, a 24-hour urine collection — or using cystatin C-based calculations — gives more reliable results.

🦪 Oyster 4: Perinephric and Renal Cyst Fluid Can Contribute to Urinary Protein

In patients with autosomal dominant polycystic kidney disease (ADPKD), massive cysts occasionally communicate with the collecting system and drain cyst fluid (which is high in protein) into the urine. This can produce significant apparent proteinuria that does not represent glomerular damage. Correlate with imaging and the clinical trajectory.

🦪 Oyster 5: Pre-Eclampsia — PCR Has Replaced 24-Hour Collection in Many Guidelines

In the urgent assessment of pre-eclampsia, the NICE 2019 and subsequent guidelines have endorsed the use of a spot PCR (threshold > 30 mg/mmol in the UK) as an alternative to the 24-hour urine collection. A PCR > 30 mg/mmol in the context of hypertension after 20 weeks gestation is diagnostic of pre-eclampsia-associated proteinuria. This has dramatically expedited inpatient assessment.

6. State-of-the-Art Updates — What Is Changing Practice Now

KDIGO 2024 CKD Guidelines — Major Revisions

The 2024 KDIGO CKD guidelines represent a landmark revision that every clinician managing renal disease must know [3]. Key changes include: (1) Retirement of the term 'microalbuminuria'; (2) A new heat-map risk matrix incorporating eGFR and ACR categories to predict CKD progression risk; (3) Lowering the ACR threshold for SGLT2 inhibitor initiation to benefit patients with ACR as low as 20 mg/mmol (200 mg/g) in conjunction with diabetes or CKD; and (4) Explicit recommendation for at-home blood pressure monitoring and first-morning ACR sampling to reduce white-coat and diurnal variability.

SGLT2 Inhibitors — Proteinuria Reduction as a Target

The CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials have collectively demonstrated that SGLT2 inhibitors reduce albuminuria by 25–40% from baseline — independent of their glycaemic effect [4,5,6]. This antiproteinuric effect is now a therapeutic target, not merely a surrogate marker. Clinicians should monitor ACR trajectories in patients on SGLT2 inhibitors: a falling ACR trajectory strongly predicts renoprotection. An ACR that fails to fall or continues rising despite SGLT2 inhibitor therapy should prompt review of adherence, drug dose, and consideration of superimposed non-diabetic nephropathy.

Finerenone — The New Kid in Town

The FIDELIO-DKD and FIGARO-DKD trials demonstrated that finerenone (a non-steroidal mineralocorticoid receptor antagonist) reduces albuminuria by approximately 30–32% and slows CKD progression in patients with diabetic kidney disease already on maximum-tolerated RAAS blockade [7]. The KDIGO 2024 guidelines now recommend considering finerenone in patients with T2DM, eGFR > 25 mL/min, ACR > 30 mg/mmol, and serum potassium within normal range — a very significant expansion of the treatment paradigm.

Automated Point-of-Care ACR Testing

Point-of-care devices (e.g., Afinion, i-STAT) can now provide a quantitative ACR result within minutes. Validation studies show excellent correlation with laboratory ACR (r > 0.95) across the A1–A3 range [8]. This has particular relevance for: remote and resource-limited settings, community-based CKD screening, and streamlining specialist clinic visits by having the ACR available at the time of consultation rather than requiring a prior laboratory visit.

Urine Biomarkers Beyond ACR — The Future

Emerging biomarkers including urinary KIM-1 (kidney injury molecule-1), NGAL (neutrophil gelatinase-associated lipocalin), MCP-1, and EGF are under active investigation as complementary to ACR for risk stratification and treatment monitoring. The Kidney Precision Medicine Project and similar initiatives are generating data to support their clinical implementation. They are not yet recommended in routine practice, but the next five years are likely to substantially reshape our proteinuria monitoring toolkit [9].

7. Diagnostic Nuances — Separating Good from Great Clinicians

History Clues That Change the Interpretation

• Time of collection: Was it first-morning, random, or post-exercise? This single question changes interpretation dramatically.

• Recent fever or acute illness: Proteinuria within two weeks of any febrile illness is functionally elevated; always recheck after four to six weeks.

• Diabetes duration and control: In early T2DM, the ACR rises before the eGFR falls — this is the therapeutic window for RAAS blockade.

• Medications: NSAIDs cause haemodynamic proteinuria; tenofovir causes tubular proteinuria (high PCR, relatively lower ACR); lithium causes tubular and glomerular injury (check both ACR and PCR); penicillamine and gold cause membranous nephropathy.

• Family history: Alport syndrome (haematuria + proteinuria + sensorineural deafness + family history), ADPKD.

• Systemic symptoms: Rashes, joint pain, sicca symptoms, weight loss — these are clues to lupus, vasculitis, amyloidosis.

Examination Findings That Change Proteinuria Interpretation

• Oedema + hypoalbuminaemia + heavy proteinuria = nephrotic syndrome — quantify urgently; check serum albumin, cholesterol, clotting (risk of thrombosis).

• Hypertension with heavy proteinuria and microscopic haematuria = nephritic pattern — think IgA, lupus nephritis, ANCA vasculitis; this is a nephrology emergency.

• Lipodystrophy + proteinuria + hypocomplementaemia = consider C3 glomerulopathy, MPGN.

• Lymphadenopathy + organomegaly + proteinuria = consider lymphoma, amyloidosis, sarcoidosis.

Urine Microscopy — the Forgotten Art

A urine microscopy performed by a trained observer (or a skilled clinician) adds enormously to proteinuria interpretation. Dysmorphic red cells and red cell casts indicate glomerulonephritis. Fatty casts and oval fat bodies (polarised microscopy showing Maltese crosses) indicate nephrotic syndrome with heavy proteinuria. Granular casts reflect tubular injury. White cell casts indicate interstitial nephritis. A urine dipstick without microscopy in a patient with significant proteinuria is only half the investigation.

THE DIPSTICK-MICROSCOPY-RATIO TRIAD

In any patient with clinically significant dipstick positivity, request the following TRIAD:

1. Urine microscopy with phase contrast (dysmorphic RBCs, casts)

2. ACR (first-morning void)

3. PCR if ACR-to-PCR discordance is suspected (myeloma screen, tubular disease)

This triad, combined with eGFR and blood pressure, answers 90% of clinical proteinuria questions without a 24-hour collection.

8. Management Intricacies — Drugs, Doses, Timing, and Pitfalls

RAAS Blockade — The Cornerstone

ACE inhibitors (ACEi) and angiotensin receptor blockers (ARBs) reduce intraglomerular pressure by preferentially dilating the efferent arteriole, thereby reducing proteinuria by 30–50% from baseline. Key clinical intricacies:

• Initiate at the ACR threshold: In diabetic nephropathy, initiate RAAS blockade when ACR > 3 mg/mmol (30 mg/g), regardless of blood pressure. In non-diabetic CKD, KDIGO 2024 recommends initiation when ACR > 30 mg/mmol (300 mg/g).

• Do NOT combine ACEi + ARB: The ONTARGET and VA-NEPHRON trials showed that dual RAAS blockade increases adverse events (hypotension, hyperkalaemia, AKI) without additional renoprotective benefit.

• Anticipate the ACR dip and GFR dip: On initiating RAAS blockade, expect an initial fall in eGFR (up to 20% is acceptable — it reflects haemodynamic, not structural, change) and a fall in ACR within four to six weeks. Failure of ACR to fall should prompt a dose increase and adherence check.

• In pregnancy, stop ACEi/ARB immediately — they are teratogenic in the second and third trimesters. Switch to methyldopa, labetalol, or nifedipine for hypertension; proteinuria in pregnancy is monitored by PCR/24-hour collection.

• Hyperkalaemia management: If potassium rises above 5.5 mmol/L on RAAS blockade, initiate low-potassium diet, remove other hyperkalaemic drugs, and consider potassium binders (patiromer, sodium zirconium cyclosilicate) before stopping the RAAS blocker.

SGLT2 Inhibitors — Initiate Earlier Than You Think

Current evidence supports initiating SGLT2 inhibitors in patients with T2DM and ACR > 3 mg/mmol (alongside RAAS blockade), and in non-diabetic CKD with eGFR 20–45 mL/min regardless of ACR [4,5]. Do not wait for ACR to reach 30 mg/mmol before starting. The window of opportunity for renoprotection is wider than previously appreciated.

Blood Pressure Targets

In patients with proteinuria > 30 mg/mmol (300 mg/g), the KDIGO 2021 BP guidelines recommend a target of < 120 mmHg systolic (standardised office measurement) if tolerated — a significantly more aggressive target than previously [10]. Every 10 mmHg reduction in systolic BP is associated with a meaningful slowing of GFR decline and reduction in cardiovascular events in proteinuric CKD.

Dietary Protein Restriction

The evidence for protein restriction in CKD has evolved. KDIGO 2024 recommends a dietary protein intake of 0.8 g/kg/day in non-dialysis CKD patients (avoiding high protein intake > 1.3 g/kg/day), while ensuring adequate caloric intake to prevent malnutrition. Very low protein diets (0.3–0.6 g/kg/day with keto acid supplements) may benefit carefully selected patients under specialist dietetic supervision.

9. When to Escalate / When to Watch — Decision Thresholds

Understanding escalation is the difference between safe management and dangerous under-referral. The following thresholds are based on current KDIGO and UK Renal Association guidelines:

Clinical Finding	Action	Urgency
ACR < 3 mg/mmol, eGFR > 60, no haematuria	Annual monitoring if risk factors (DM, HTN); reassure if low-risk	Routine
ACR 3–30 mg/mmol (A2), eGFR > 45	Initiate RAAS blockade + SGLT2i if T2DM; optimise BP; repeat ACR in 3 months	Semi-urgent (4–6 wks)
ACR > 30 mg/mmol (A3), any eGFR	Nephrology referral; investigate for underlying cause; intensify RAAS + SGLT2i	Urgent (within 4 wks)
ACR > 220 mg/mmol (nephrotic range)	Same-day or next-day nephrology referral; check serum albumin, clotting, renal function	Urgent to emergency
ACR > 30 + active urinary sediment (RBC casts)	Emergency nephrology referral — suspect glomerulonephritis or vasculitis	Emergency
PCR >> ACR (discordant)	UPEP, serum FLC, Bence-Jones — rule out myeloma before any other explanation	Urgent
Rapidly rising ACR + falling eGFR (> 25% over 3 months)	Nephrology referral; consider biopsy — may represent crescentic GN, vasculitis, or accelerated IgA	Emergency
Proteinuria in pregnancy (PCR > 30 mg/mmol + hypertension)	In-patient assessment for pre-eclampsia; involve obstetric team immediately	Emergency

WATCH SAFELY — THESE DO NOT NEED IMMEDIATE REFERRAL

Isolated trace/1+ dipstick in a young patient without haematuria or hypertension: Confirm with first-morning ACR. If normal, consider orthostatic proteinuria split test.

Borderline ACR (4–8 mg/mmol) in a patient with known CKD already under nephrology: Document and monitor at next scheduled review.

Transient proteinuria after acute illness or surgery: Repeat ACR 4–6 weeks after full recovery before actioning.

10. Summary: The PROTEIN Framework

MNEMONIC: P-R-O-T-E-I-N

P — Pick the right test (dipstick = screen; ACR = monitor; PCR = broad net; 24-hr = gold standard)

R — Ratios need stable creatinine (beware extremes of muscle mass)

O — Orthostatic & transient causes first (rule out before diagnosing CKD)

T — Timing matters (first-morning void preferred; avoid post-exercise, febrile)

E — Electrophoresis if PCR >> ACR (never miss myeloma)

I — Interpret TRENDS not single values (KDIGO: 2/3 samples over 3 months)

N — Never compare ACR with PCR directly (like for like always)

Comprehensive Comparison: Proteinuria Tests at a Glance

Feature	Dipstick	ACR (Spot)	PCR (Spot)	24-Hour Urine
What it detects	Albumin only	Albumin only	All proteins	All proteins
Non-albumin proteinuria	Misses it	Misses it	Detects it	Detects it
Preferred sample	Spot/random	First-morning void	First-morning void	Full 24-hr timed
Concentration effect	High — affects result	Corrected by creatinine	Corrected by creatinine	Not applicable
Muscle mass effect	None	Significant	Significant	Significant
Ease of use	Very easy	Easy	Easy	Burdensome
Reliability	Low (qualitative)	High	High	High if complete
Use in CKD monitoring	Screening only	First-line standard	Supplementary	Selected cases
Use in myeloma screen	NOT suitable	NOT suitable	Partial	With UPEP
Use in pre-eclampsia	Screening	Acceptable	Recommended	Acceptable
Nephrotic threshold	> 4+ or ~300+ mg/dL	> 220 mg/mmol	> 350 mg/mmol	> 3.5 g/day

11. References

1. 1. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7-11.

2. 2. Methven S, MacGregor MS, Traynor JP, Hair M, O'Reilly DSJ, Deighan CJ. Comparison of urinary albumin and urinary total protein as predictors of patient outcomes in CKD. Am J Kidney Dis. 2011;57(1):21-28.

3. 3. KDIGO 2024 CKD Guideline Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314.

4. 4. Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306.

5. 5. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446.

6. 6. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127.

7. 7. Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-2229.

8. 8. Lamb EJ, MacKenzie F, Stevens PE. How should proteinuria be detected and measured? Ann Clin Biochem. 2009;46(Pt 3):205-217.

9. 9. Coca SG, Nadkarni GN, Huang Y, et al. Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J Am Soc Nephrol. 2017;28(9):2786-2793.

10. 10. KDIGO 2021 Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87.

11. 11. Viswanathan G, Upadhyay A. Assessment of proteinuria. Adv Chronic Kidney Dis. 2011;18(4):243-248.

12. 12. Naresh CN, Hayen A, Weening A, Craig JC, Chadban SJ. Day-to-day variability in spot urine albumin-creatinine ratio. Am J Kidney Dis. 2013;62(6):1095-1101.

13. 13. National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. NICE Guideline NG133. 2019.

PROTEINURIA TESTING: Dipstick, ACR, PCR, and 24-Hour Collections — Clearing the Confusion Once and for All